TriangleZanzalintinib (NCT06926634)
Zanzalintinib trial for High Grade Neuroendocrine Neoplasms (NCT06926634). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with high-grade neuroendocrine neoplasms and measurable disease, excluding small-cell lung and Merkel-cell cancer. Their latest chemotherapy must leave stable disease or a partial response, allowing a chemotherapy break.
The idea: use zanzalintinib as maintenance treatment. It blocks MET, VEGFR2, AXL and MER signals involved in tumor growth and blood-vessel formation. Patients take 60 milligrams by mouth daily for up to three years. Researchers measure time without progression. Previous cabozantinib or zanzalintinib is excluded.
This phase 2 study plans 32 patients. Washington University sponsors its recruiting St Louis site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.